Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer

  1. Young Seok Ju
  2. Ludmil B Alexandrov
  3. Moritz Gerstung
  4. Inigo Martincorena
  5. Serena Nik-Zainal
  6. Manasa Ramakrishna
  7. Helen R Davies
  8. Elli Papaemmanuil
  9. Gunes Gundem
  10. Adam Shlien
  11. Niccolo Bolli
  12. Sam Behjati
  13. Patrick S Tarpey
  14. Jyoti Nangalia
  15. Charles E Massie
  16. Adam P Butler
  17. Jon W Teague
  18. George S Vassiliou
  19. Anthony R Green
  20. Ming-Qing Du
  21. Ashwin Unnikrishnan
  22. John E Pimanda
  23. Bin Tean Teh
  24. Nikhil Munshi
  25. Mel Greaves
  26. Paresh Vyas
  27. Adel K El-Naggar
  28. Tom Santarius
  29. V Peter Collins
  30. Richard Grundy
  31. Jack A Taylor
  32. D Neil Hayes
  33. David Malkin
  34. ICGC Breast Cancer Group
  35. ICGC Chronic Myeloid Disorders Group
  36. ICGC Prostate Cancer Group
  37. Christopher S Foster
  38. Anne Y Warren
  39. Hayley C Whitaker
  40. Daniel Brewer
  41. Rosalind Eeles
  42. Colin Cooper
  43. David Neal
  44. Tapio Visakorpi
  45. William B Isaacs
  46. G Steven Bova
  47. Adrienne M Flanagan
  48. P Andrew Futreal
  49. Andy G Lynch
  50. Patrick F Chinnery
  51. Ultan McDermott
  52. Michael R Stratton
  53. Peter J Campbell  Is a corresponding author
  1. Wellcome Trust Sanger Institute, United Kingdom
  2. University of Cambridge, United Kingdom
  3. Cambridge University Hospitals NHS Foundation Trust, United Kingdom
  4. University of New South Wales, Australia
  5. National Cancer Centre, Singapore
  6. Dana-Farber Cancer Institute, United States
  7. Institute of Cancer Research, Sutton, United Kingdom
  8. University of Oxford, United Kingdom
  9. MD Anderson Cancer Center, United States
  10. University of Nottingham, United Kingdom
  11. National Institute of Health, United States
  12. University of North Carolina, United States
  13. University of Toronto, Canada
  14. University of Liverpool, United Kingdom
  15. University of East Anglia, United Kingdom
  16. University of Tampere, Finland
  17. Johns Hopkins University, United States
  18. Royal National Orthopaedic Hospital, United Kingdom
  19. Newcastle University, United Kingdom

Abstract

Recent sequencing studies have extensively explored the somatic alterations present in the nuclear genomes of cancers. Although mitochondria control energy metabolism and apoptosis, the origins and impact of cancer-associated mutations in mtDNA are unclear. Here, we analysed somatic alterations in mtDNA from 1,675 tumors. We identified 1,907 somatic substitutions, which exhibited dramatic replicative strand bias, predominantly C>T and A>G on the mitochondrial heavy strand. This strand-asymmetric signature differs from those found in nuclear cancer genomes but matches the inferred germline process shaping primate mtDNA sequence content. Numbers of mtDNA mutations showed considerable heterogeneity across tumor types. Missense mutations were selectively neutral and often gradually drifted towards homoplasmy over time. In contrast, mutations resulting in protein truncation undergo negative selection and were almost exclusively heteroplasmic. Our findings indicate that the endogenous mutational mechanism has far greater impact than any other external mutagens in mitochondria, and is fundamentally linked to mtDNA replication.

Article and author information

Author details

  1. Young Seok Ju

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. Ludmil B Alexandrov

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Moritz Gerstung

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Inigo Martincorena

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Serena Nik-Zainal

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Manasa Ramakrishna

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Helen R Davies

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Elli Papaemmanuil

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Gunes Gundem

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Adam Shlien

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Niccolo Bolli

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Sam Behjati

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  13. Patrick S Tarpey

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  14. Jyoti Nangalia

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  15. Charles E Massie

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  16. Adam P Butler

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  17. Jon W Teague

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  18. George S Vassiliou

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  19. Anthony R Green

    University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  20. Ming-Qing Du

    Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  21. Ashwin Unnikrishnan

    University of New South Wales, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
  22. John E Pimanda

    University of New South Wales, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
  23. Bin Tean Teh

    National Cancer Centre, Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  24. Nikhil Munshi

    Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  25. Mel Greaves

    Institute of Cancer Research, Sutton, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  26. Paresh Vyas

    University of Oxford, Oxford, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  27. Adel K El-Naggar

    MD Anderson Cancer Center, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  28. Tom Santarius

    Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  29. V Peter Collins

    Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  30. Richard Grundy

    University of Nottingham, Nottingham, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  31. Jack A Taylor

    National Institute of Health, Triangle, North Carolina, United States
    Competing interests
    The authors declare that no competing interests exist.
  32. D Neil Hayes

    University of North Carolina, Chapel Hill, United States
    Competing interests
    The authors declare that no competing interests exist.
  33. David Malkin

    University of Toronto, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  34. ICGC Breast Cancer Group

    Competing interests
    The authors declare that no competing interests exist.
  35. ICGC Chronic Myeloid Disorders Group

    Competing interests
    The authors declare that no competing interests exist.
  36. ICGC Prostate Cancer Group

    Competing interests
    The authors declare that no competing interests exist.
  37. Christopher S Foster

    University of Liverpool, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  38. Anne Y Warren

    Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  39. Hayley C Whitaker

    University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  40. Daniel Brewer

    University of East Anglia, Norwich, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  41. Rosalind Eeles

    Institute of Cancer Research, Sutton, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  42. Colin Cooper

    Institute of Cancer Research, Sutton, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  43. David Neal

    University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  44. Tapio Visakorpi

    University of Tampere, Tampere, Finland
    Competing interests
    The authors declare that no competing interests exist.
  45. William B Isaacs

    Johns Hopkins University, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  46. G Steven Bova

    University of Tampere, Tampere, Finland
    Competing interests
    The authors declare that no competing interests exist.
  47. Adrienne M Flanagan

    Royal National Orthopaedic Hospital, Middlesex, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  48. P Andrew Futreal

    MD Anderson Cancer Center, Houston, United States
    Competing interests
    The authors declare that no competing interests exist.
  49. Andy G Lynch

    University of Cambridge, Cambridge, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  50. Patrick F Chinnery

    Newcastle University, Newcastle-upon-tyne, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  51. Ultan McDermott

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  52. Michael R Stratton

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  53. Peter J Campbell

    Wellcome Trust Sanger Institute, Hinxton, United Kingdom
    For correspondence
    pc8@sanger.ac.uk
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Human subjects: We obtained informed consent and consent to publish from participants enrolled in this study.Ethical approval references:Genome Analysis of myeloid and lymphoid malignancies (10/H0306/40)Genomic Analysis of Mesothelioma (11/EE/0444)Myeloid and lymphoid cancer genome analysis (07/S1402/90)The Treatment of Down Syndrome Children with Acute Myeloid Leukemia and Myelodysplastic Syndrome(AAML0431)CLL (chronic lymphocytic leukaemia) genome analysis (07/Q0104/3)CGP-Exome sequencing of Down syndrome associated acute myeloid leukemia samples (IRB 13-010133)Cancer Genome Project - Global approaches to characterising the molecular basis of paediatric ependymoma (05/MRE04/70)PREDICT-Cohort (09/H0801/96)ICGC Prostate (Evaluation of biomarkers in urological diseases) (LREC 03/018)ICGC Prostate (779) (Prostate Complex CRUK Sample Cohort) (MREC/01/4/061)ICGC Prostate (Tissue collection at radical prostatectomy) (CRE-2011.373)Somatic molecular genetics of human cancers, melanoma and myeloma (Dana Farber Cancer Institute)(08/H0308/303)Breast Cancer Genome Analysis for the International Cancer Genome Consortium Working Group (09/H0306/36)Genome analysis of tumours of the bone (09/H0308/165)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 12,921
    views
  • 2,113
    downloads
  • 324
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Young Seok Ju
  2. Ludmil B Alexandrov
  3. Moritz Gerstung
  4. Inigo Martincorena
  5. Serena Nik-Zainal
  6. Manasa Ramakrishna
  7. Helen R Davies
  8. Elli Papaemmanuil
  9. Gunes Gundem
  10. Adam Shlien
  11. Niccolo Bolli
  12. Sam Behjati
  13. Patrick S Tarpey
  14. Jyoti Nangalia
  15. Charles E Massie
  16. Adam P Butler
  17. Jon W Teague
  18. George S Vassiliou
  19. Anthony R Green
  20. Ming-Qing Du
  21. Ashwin Unnikrishnan
  22. John E Pimanda
  23. Bin Tean Teh
  24. Nikhil Munshi
  25. Mel Greaves
  26. Paresh Vyas
  27. Adel K El-Naggar
  28. Tom Santarius
  29. V Peter Collins
  30. Richard Grundy
  31. Jack A Taylor
  32. D Neil Hayes
  33. David Malkin
  34. ICGC Breast Cancer Group
  35. ICGC Chronic Myeloid Disorders Group
  36. ICGC Prostate Cancer Group
  37. Christopher S Foster
  38. Anne Y Warren
  39. Hayley C Whitaker
  40. Daniel Brewer
  41. Rosalind Eeles
  42. Colin Cooper
  43. David Neal
  44. Tapio Visakorpi
  45. William B Isaacs
  46. G Steven Bova
  47. Adrienne M Flanagan
  48. P Andrew Futreal
  49. Andy G Lynch
  50. Patrick F Chinnery
  51. Ultan McDermott
  52. Michael R Stratton
  53. Peter J Campbell
(2014)
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer
eLife 3:e02935.
https://doi.org/10.7554/eLife.02935

Share this article

https://doi.org/10.7554/eLife.02935

Further reading

    1. Genetics and Genomics
    Junhong Choi, Wei Chen ... Jay Shendure
    Research Article

    One of the goals of synthetic biology is to enable the design of arbitrary molecular circuits with programmable inputs and outputs. Such circuits bridge the properties of electronic and natural circuits, processing information in a predictable manner within living cells. Genome editing is a potentially powerful component of synthetic molecular circuits, whether for modulating the expression of a target gene or for stably recording information to genomic DNA. However, programming molecular events such as protein-protein interactions or induced proximity as triggers for genome editing remains challenging. Here, we demonstrate a strategy termed ‘P3 editing’, which links protein-protein proximity to the formation of a functional CRISPR-Cas9 dual-component guide RNA. By engineering the crRNA:tracrRNA interaction, we demonstrate that various known protein-protein interactions, as well as the chemically induced dimerization of protein domains, can be used to activate prime editing or base editing in human cells. Additionally, we explore how P3 editing can incorporate outputs from ADAR-based RNA sensors, potentially allowing specific RNAs to induce specific genome edits within a larger circuit. Our strategy enhances the controllability of CRISPR-based genome editing, facilitating its use in synthetic molecular circuits deployed in living cells.

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics
    Kira Breunig, Xuifen Lei ... Luiz O Penalva
    Research Article

    RNA binding proteins (RBPs) containing intrinsically disordered regions (IDRs) are present in diverse molecular complexes where they function as dynamic regulators. Their characteristics promote liquid-liquid phase separation (LLPS) and the formation of membraneless organelles such as stress granules and nucleoli. IDR-RBPs are particularly relevant in the nervous system and their dysfunction is associated with neurodegenerative diseases and brain tumor development. Serpine1 mRNA-binding protein 1 (SERBP1) is a unique member of this group, being mostly disordered and lacking canonical RNA-binding domains. We defined SERBP1’s interactome, uncovered novel roles in splicing, cell division and ribosomal biogenesis, and showed its participation in pathological stress granules and Tau aggregates in Alzheimer’s brains. SERBP1 preferentially interacts with other G-quadruplex (G4) binders, implicated in different stages of gene expression, suggesting that G4 binding is a critical component of SERBP1 function in different settings. Similarly, we identified important associations between SERBP1 and PARP1/polyADP-ribosylation (PARylation). SERBP1 interacts with PARP1 and its associated factors and influences PARylation. Moreover, protein complexes in which SERBP1 participates contain mostly PARylated proteins and PAR binders. Based on these results, we propose a feedback regulatory model in which SERBP1 influences PARP1 function and PARylation, while PARylation modulates SERBP1 functions and participation in regulatory complexes.